President and CEOOfficers of the CorporationBoard of TrusteesFoundation BoardLeadership CouncilAbout Joslin ResearchAdvocacy & Gov't AffairsHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareMake an AppointmentBillingPatient PortalInfo for Healthcare Professionals
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Professional Education

Joslin Diabetes Center is a leader in continuing education for healthcare professionals. Joslin's CME and CE activities promote the highest standards of care, drawing on up-to-date medical literature as well as cutting-edge research conducted at Joslin to provide current, relevant, and evidence-based findings from Joslin faculty and other experts.

Our mission is to help providers offer their patients optimal management of diabetes and its related conditions, improved health outcomes, and enhanced quality of life. To that end, we provide continuing medical education for all members of the diabetes team - physicians, physician assistants, nurse practitioners, nurses, dietitians, pharmacists, and other healthcare professionals- in a variety of formats, both live and online, to suit your schedule and preferred learning style.



Proven Success with Educational Outcomes

 

Joslin Diabetes Center has been at the forefront of measuring educational outcomes for our activities, based on the levels defined by Moore et al.1 We have been involved in several specific projects that measure the impact of our educational activities on clinician performance measures (Level 5) and patient outcomes measures (Level 6). Please click on the link below to read about one of these initiatives entitled Targeting Type 2 Diabetes: Achieving Glycemic and Cardiometabolic Goals. This initiative was supported by educational grants from GlaxoSmithKline LLC and Merck Sharpe and Dohme Corp.

Click here for Final Report

1 Moore DE Jr, Green JS, Gallis HA. Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities. J Contin Educ Health Prof. 2009;29(1):1-15.



Current Enduring Activities

Advances in Cardiometabolic Health 2014--Webcast Series

This internet enduring material was developed from the original live event held on June 19-21, 2014 in Boston, MA. Click on the title above to go to the activity.

Cardiometabolic syndrome is a constellation of risk factors that increase the risk of developing cardiovascular disease. While there is some debate as to whether this is truly a syndrome with interconnecting pathophysiologic roots, the clinical implications are clear: these risk factors must be addressed early and effectively to protect our patients from the epidemic of cardiovascular disease.

This comprehensive course developed by Joslin Diabetes Center focuses on practical aspects of primary care for preventing, identifying, and managing cardiometabolic syndrome and cardiovascular disease, including complications and comorbidities. The goal is to improve front-line physicians’ clinical skills so they can address these abnormalities in a timely and effective manner.

Note: This tuition-based course is offered through our partner myCME. Expiration date: February 20, 2016.

*****

Patient Case Study: An Obese Male With Very High A1C and High Motivation

Many clinicians delay initiation of needle-delivered medications as long as possible in T2DM, allowing patients to use lifestyle modifications plus metformin and eventually additional oral medications for an extended time, even when outcomes remain suboptimal. Not all patients benefit from this conservative approach, however. In the case presented here, the combination of an elevated A1C and a patient’s commitment to do whatever it takes to manage his diabetes demonstrate the value of expediting advancement to non-oral antidiabetes medications.

This activity is supported by an educational grant from Lilly USA, LLC and is offered through our partner myCME. Expiration date: June 16, 2016.

*****

Biosimilar Insulins and Their Implications for Clinical Practice

Biosimilar medications are “highly similar” to an already FDA-approved biological product. One biosimilar is approved in the US, with more sure to follow in the near future, including a biosimilar insulin that is likely to have a significant impact on diabetes management. Although they will be responsible for ensuring safe and effective use of biosimilars, many clinicians are not familiar with the distinctions between biosimilars and generic drugs, including the different approval processes and regulatory issues surrounding these agents. These webcasts present the perspective of an endocrinologist versed in regulatory approval processes, and endocrinologist with expertise in insulin management, and a clinical pharmacist.

Link to Roundtable webcast. This activity is supported by an educational grant from Lilly USA, LLC and is offered through our partner myCME. Expiration date: May 5, 2016.

Link to Q&A webcast. This activity is supported by an educational grant from Lilly USA, LLC and is offered through our partner myCME. Expiration date: July 10, 2016.

*****

SGLT2 Inhibitors in Type 2 Diabetes: Incorporating New Approaches Into Practice Through an Interdisciplinary Exploration

Type 2 diabetes mellitus (T2DM) remains undertreated in many patients, partly due to the progressive nature of the disease and the limitations of traditional therapies. Despite the plethora of available therapeutic options, adequate glycemic control is still often difficult to achieve, leading to serious complications. In this multidisciplinary Roundtable discussion, 4 key experts will provide their unique perspectives about SGLT2 inhibitors and their role in T2DM treatment. Two case studies allow the learner to apply knowledge to simulated patients.

Link to Roundtable webcast. This activity is supported by an educational grant from AstraZeneca LP and is offered through our partner myCME. Expiration date: June 29, 2016.

Link to Case 1: A Patient With Hypertension and Poorly Controlled Type 2 Diabetes. This activity is supported by an educational grant from AstraZeneca LP and is offered through our partner myCME. Expiration date: June 29, 2016.

Link to Case 2: A Complex Patient With Type 2 Diabetes and Moderate CKD. This activity is supported by an educational grant from AstraZeneca LP and is offered through our partner myCME. Expiration date: June 29, 2016.


Diabetes Screening and Management in Your Practice.pdf

 

Joslin at ADA 2015

Joslin held an engaging symposium in conjunction with the ADA's 75th Scientific Sessions:

Complementary Treatments to Enhance Insulin Efficacy: Theory and Strategies

Check back for the upcoming enduring material monograph that will be developed based on the live symposium.

Joslin Clinical Guidelines

To assist physicians and other healthcare professionals in managing the care of their patients with diabetes, Joslin offers approved clinical guidelines on a variety of topics including Adult Diabetes, Pharmacological Management of Type 2 Diabetes, and Continuous Glucose Monitors.

ACCME Awards Joslin CME Accreditation with Commendation